December 7, 2016 — Abiomed Inc. announced it has expanded its U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for Impella heart pump use in high-risk percutaneous coronary interventions (PCI) to include the Impella CP heart pump. The Impella heart pumps provide the only minimally invasive treatment option with the unique ability to stabilize the patient's hemodynamics and unload the left ventricle of the heart, which allows the muscle to rest and recover its native function.

December 7, 2016 — At the 102nd Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), the separately managed healthcare business of Siemens AG presented itself for the first time under its new brand name, Siemens Healthineers. The company featured several new releases, including two new features on the PURE platform for Siemens’ Artis zee, Artis Q and Artis Q.zen angiography systems.

Researchers at Princess Alexandra Hospital, Brisbane, Australia, have demonstrated that cardiac amyloidosis (abnormal deposits of proteins in the heart), which is notoriously difficult to diagnose, can be visualized noninvasively with positron emission tomography (PET) using the radiotracer fluorine-18 (F-18)-florbetaben. The study is published in the November issue of The Journal of Nuclear Medicine.